The association between menstrual cycle characteristics and cardiometabolic outcomes in later life: a retrospective matched cohort study of 704,743 women from the UK
Open Access
- 20 March 2023
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 21 (1) , 1-14
Abstract
Background: Female reproductive factors are gaining prominence as factors that enhance cardiovascular disease (CVD) risk; nonetheless, menstrual cycle characteristics are under-recognized as a factor associated with CVD. Additionally, there is limited data from the UK pertaining to menstrual cycle characteristics and CVD risk. Methods: A UK retrospective cohort study (1995–2021) using data from a nationwide database (The Health Improvement Network). Women aged 18–40 years at index date were included. 252,325 women with history of abnormal menstruation were matched with up to two controls. Two exposures were examined: regularity and frequency of menstrual cycles; participants were assigned accordingly to one of two separate cohorts. The primary outcome was composite cardiovascular disease (CVD). Secondary outcomes were ischemic heart disease (IHD), cerebrovascular disease, heart failure (HF), hypertension, and type 2 diabetes mellitus (T2DM). Cox proportional hazards regression models were used to derive adjusted hazard ratios (aHR) of cardiometabolic outcomes in women in the exposed groups compared matched controls. Results: During 26 years of follow-up, 20,605 cardiometabolic events occurred in 704,743 patients. Compared to women with regular menstrual cycles, the aHRs (95% CI) for cardiometabolic outcomes in women with irregular menstrual cycles were as follows: composite CVD 1.08 (95% CI 1.00–1.19), IHD 1.18 (1.01–1.37), cerebrovascular disease 1.04 (0.92–1.17), HF 1.30 (1.02–1.65), hypertension 1.07 (1.03–1.11), T2DM 1.37 (1.29–1.45). The aHR comparing frequent or infrequent menstrual cycles to menstrual cycles of normal frequency were as follows: composite CVD 1.24 (1.02–1.52), IHD 1.13 (0.81–1.57), cerebrovascular disease 1.43 (1.10–1.87), HF 0.99 (0.57–1.75), hypertension 1.31 (1.21–1.43), T2DM 1.74 (1.52–1.98). Conclusions: History of either menstrual cycle irregularity or frequent or infrequent cycles were associated with an increased risk of cardiometabolic outcomes in later life. Menstrual history may be a useful tool in identifying women eligible for periodic assessment of their cardiometabolic health.Keywords
This publication has 57 references indexed in Scilit:
- Alcohol consumption screening of newly-registered patients in primary care: a cross-sectional analysisBritish Journal of General Practice, 2013
- Menstrual Irregularity and Cardiovascular MortalityThe Journal of Clinical Endocrinology & Metabolism, 2011
- Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN)Pharmacoepidemiology and Drug Safety, 2010
- PHP88 HOW DOES THE HEALTH IMPROVEMENT NETWORK (THIN) DATA ON PREVALENCE OF CHRONIC DISEASES COMPARE WITH NATIONAL FIGURES?Value in Health, 2009
- Creating medical and drug code lists to identify cases in primary care databasesPharmacoepidemiology and Drug Safety, 2009
- Contraceptive Hormone Use and Cardiovascular DiseaseJACC, 2009
- Estrogen is a modulator of vascular inflammationIUBMB Life, 2008
- Accuracy of Reporting of Menstrual Cycle LengthAmerican Journal of Epidemiology, 2007
- Irregularidade do ciclo menstrual no menacme como marcador para fatores de risco cardiovasculares na pós-menopausaArchives of Endocrinology and Metabolism, 2006
- What are the Read Codes?Health Libraries Review, 1994